Essays on Science and SocietyScience & SciLifeLab Prize

HIV-specific B cell response in patients with broadly neutralizing serum activity

See allHide authors and affiliations

Science  04 Dec 2015:
Vol. 350, Issue 6265, pp. 1175-1176
DOI: 10.1126/science.aad7133

Figures

  • Isolation and testing of broadly neutralizing antibodies against HIV.

    (A) Five to 10% of HIV-positive individuals eventually develop broad and potent serum neutralizing activity. (B) Fluorescence-activated cell sorting plot of a single-cell sort of gp140-specific B cells. (C) Single-cell antibody cloning of differently expanded B cell clones shown in red, dark blue, and light blue, respectively. (D) In vivo testing of the therapeutic and protective effect of antibodies in humanized mice and nonhuman primates. (E) Selection of highly potent and broad monoclonal antibodies. (F) Clinical testing in phase-I human trials.

    ILLUSTRAITON: P. HUEY/SCIENCE
  • PHOTO: JONATHAN ABRAHAM
  • PHOTO: JOHNATHAN ABRAHAM

Navigate This Article